Construction of A Microfluidic Intestine-liver-breast Cancer Chip and Analysis of Its Application in PK-PD <italic style="font-style: italic">in Vitro</italic> of Drugs

Heng-shun HUANG; Jiu DENG; Xiao-rui LI; Zong-zheng CHEN; Yong LUO

doi:10.13422/j.cnki.syfjx.20191749

您当前的位置：

首页 >

文章列表页 >

Construction of A Microfluidic Intestine-liver-breast Cancer Chip and Analysis of Its Application in PK-PD in Vitro of Drugs

Pharmacy and Processing | 更新时间：2021-04-16

- Construction of A Microfluidic Intestine-liver-breast Cancer Chip and Analysis of Its Application in PK-PD in Vitro of Drugs
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 2, Pages: 104-112(2020)
- 作者机构：
  
  1.大连理工大学　化工学院，辽宁大连　 116023
  2.深圳大学　第一附属医院，广东深圳　 518035
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20191749
  CLC： R22; R28; C37; R94; Q2
- Received：25 March 2019，
  
  Published Online：17 May 2019，
  
  Published：20 January 2020
- 稿件说明：
移动端阅览
Heng-shun HUANG, Jiu DENG, Xiao-rui LI, et al. Construction of A Microfluidic Intestine-liver-breast Cancer Chip and Analysis of Its Application in PK-PD in Vitro of Drugs[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(2): 104-112.
DOI：

Heng-shun HUANG, Jiu DENG, Xiao-rui LI, et al. Construction of A Microfluidic Intestine-liver-breast Cancer Chip and Analysis of Its Application in PK-PD in Vitro of Drugs[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(2): 104-112. DOI： 10.13422/j.cnki.syfjx.20191749.

摘要

目的：

基于微流控技术构建肠-肝-乳腺癌多器官芯片并将其用于药物的体外药物代谢动力学-药物效应动力学(PK-PD)研究。

方法：

利用微流控技术构建包含4层聚二甲基硅氧烷(PDMS)基板和2层聚甲基丙烯酸甲酯(PMMA)盖板的多器官芯片；分别使用CellTracker Red/Green和Hoechst对生长21 d的人结肠癌细胞株Caco-2细胞层和生长3 d的人脐静脉内皮细胞株HUVEC细胞层进行染色，考察细胞间的连接情况，通过测定2 g·L

-1

荧光素钠和33.28 mg·L

-1

普萘洛尔跨细胞层的透过率来验证所建肠模块的功能；通过比较125 μmol·L

-1

环磷酰胺经过常规孔板中人肝癌细胞株HepG2细胞和芯片肝模块处理48 h后对人乳腺癌细胞株MCF-7细胞的抑制率来考察肝模块的代谢水平；通过检测芯片中HepG2细胞分泌白蛋白情况验证肝模块的合成功能；将Caco-2细胞层，HUVEC细胞层，HepG2细胞层，MCF-7细胞层及透析膜组装在芯片上，在芯片上层通道中通入含55 mg·L

-1

普萘洛尔的培养液4 h后换成正常培养液，检测72 h内各个时间点下层循环培养液中普萘洛尔的质量浓度，绘制药-时曲线；在芯片上层循环液中分别通入含125 μmol·L

-1

环磷酰胺，5 μmol·L

-1

紫杉醇，50 μmol·L

-1

卡培他滨的培养液，研究3种抗肿瘤药物在芯片上对MCF-7细胞层的72 h抑制率，并将该结果与96孔板结果进行比较。

结果：

构建的芯片运行良好，Caco-2和HUVEC细胞层均连接紧密，荧光素钠和普萘洛尔在细胞层间的透过率证明构建的肠模块具有良好的吸收转运功能；125 μmol·L

-1

环磷酰胺经孔板上的HepG2细胞代谢后对MCF-7的抑制率22.12%，未被代谢的环磷酰胺对MCF-7的抑制率1.84%；而125 μmol·L

-1

环磷酰胺从芯片肝模块上层注入后对MCF-7的抑制率提升至32.13%，而从芯片肝模块下层注入后对MCF-7的抑制率7.23%；测得普萘洛尔质量浓度在芯片上随时间变化的趋势与体内基本一致；125 μmol·L

-1

环磷酰胺在孔板上对MCF-7的抑制率比芯片上要低，而5 μmol·L

-1

紫杉醇和50 μmol·L

-1

卡培他滨在孔板上对MCF-7的抑制率则高于芯片结果。

结论：

构建的肠-肝-乳腺癌多器官芯片具有肠的吸收转运功能、肝的代谢功能；该芯片能够反映普萘洛尔在体内的药代动力学特性，同时可用于紫杉醇和卡培他滨的药效学研究。

Abstract

Objective:

A multi-organ chip of intestine-liver-breast cancer was constructed based on microfluidic technology and used for pharmacokinetics-pharmacodynamics (PK-PD) study of drugs

in vitro

Method:

A multi-organ chip comprising a 4-layer polydimethylsiloxane (PDMS) substrate and a 2-layer poly(methyl methacrylate) (PMMA) cover was constructed by microfluidic technology. The connection between cells was investigated by staining the 21-day-grown human colon cancer cell line Caco-2 cell layer and the 3-day-grown human umbilical vein endothelial cell line HUVEC cell layer with CellTracker Red/Green and Hoechst

respectively. The transmission rates of 2 g·L

-1

fluorescein sodium and 33.28 mg·L

-1

propranolol acrossing the cell layer were employed to verify the function of the constructed intestinal module. The metabolic level of the liver module was investigated by comparing the inhibition rate of 125 μmol·L

-1

cyclophosphamide against human breast cancer cell line MCF-7 cells treated with human hepatoma cell line HepG2 cells in a conventional well plate and chip liver module for 48 h. The secretion of albumin by HepG2 cells in the chip was detected to verify the synthesis function of hepatic module. Caco-2 cell layer

HUVEC cell layer

HepG2 cell layer

MCF-7 cell layer and dialysis membrane were assembled on the chip

the culture medium containing 55 mg·L

-1

propranolol was injected into the upper channel of the chip for 4 h

and then changed into the normal culture solution. The mass concentration of propranolol in the lower circulating culture medium at each time point within 72 h was determined

and the drug-time curve was drawn. The culture medium containing 125 μmol·L

-1

cyclophosphamide

5 μmol·L

-1

paclitaxel

50 μmol·L

-1

capecitabine was injected into the circulating fluid in the upper layer of the chip

in order to study the inhibition rates of the three anti-tumor drugs on the MCF-7 cell layer on the chip within 72 h

and the results were compared with those of the 96-well plate.

Result:

The constructed chip performed well. The Caco-2 and HUVEC cell layers were tightly connected. The transmission of fluorescein sodium and propranolol between the cell layers demonstrated that the constructed intestinal module had good absorption and transport function. The inhibition rate of MCF-7 by 125 μmol·L

-1

cyclophosphamide after metabolism of HepG2 cells on the well plate was 22.12%

and the inhibition rate of MCF-7 by the unmetabolized cyclophosphamide was 1.84%. The inhibition rate of MCF-7 increased to 32.13%after injected 125 μmol·L

-1

cyclophosphamide from the upper layer of the chip liver module

and the inhibition rate of MCF-7 after injection from the lower layer of the chip liver module was 7.23%. The mass concentration of propranolol on the chip changed with time

which was basically consistent with that

in vivo

. The inhibition rate of MCF-7 on the plate with 125 μmol·L

-1

cyclophosphamide was lower than that on the chip

and the inhibition rates of MCF-7 on the plate with 5 μmol·L

-1

paclitaxel and 50 μmol·L

-1

capecitabine were higher than those on the chip.

Conclusion:

The constructed multi-organ chip of intestine-liver-breast cancer has the absorption and transport function of the intestine and the metabolic function of the liver. The chip can reflect the pharmacokinetic properties of propranolol

in vivo

and can be used for pharmacodynamic studies of paclitaxel and capecitabine.

关键词

Keywords

references

B Seruga ， A Ocana ， E Amir ， et al . Failures in phase Ⅲ：causes and consequences [J]． Clin Cancer Res ， 2015 ， 21 ( 20 )： 4552 - 4560 .

J H Sung ， B Srinivasan ， M B Esch ， et al . Using physiologically-based pharmacokinetic-guided ”body-on-a-chip” systems to predict mammalian response to drug and chemical exposure [J]． Exp Biol Med(Maywood) ， 2014 ， 239 ( 9 )： 1225 - 1239 .

C ZHANG ， Z Q ZHAO ， N A Abdul-Rahim ， et al . Towards a human-on-chip：culturing multiple cell types on a chip with compartmentalized microenvironments [J]． Lab Chip ， 2009 ， 9 ( 22 )： 3185 - 3192 .

L R Volpatti ， A K Yetisen ． Commercialization of microfluidic devices [J]． Trends Biotechnol ， 2014 ， 32 ( 7 )： 347 - 350 .

郭明星，赵保胜，高晓燕．微流控技术在医药领域的研究进展 [J]．中国实验方剂学杂志， 2012 ， 18 ( 18 )： 323 - 327 .

S N Bhatia ， D E Ingber ． Microfluidic organs-on-chips [J]． Nat Biotechnol ， 2014 ， 32 ( 8 )： 760 - 772 .

H J Kim ， D Huh ， G Hamilton ， et al . Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow [J]． Lab Chip ， 2012 ， 12 ( 12 )： 2165 - 2174 .

Y Nakao ， H Kimura ， Y Sakai ， et al . Bile canaliculi formation by aligning rat primary hepatocytes in a microfluidic device [J]． Biomicrofluidics ， 2011 ， 5 ( 2 )： 22212 .

P J Lee ， P J Hung ， L P Lee ． An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture [J]． Biotechnol Bioeng ， 2007 ， 97 ( 5 )： 1340 - 1346 .

B J Kane ， M J Zinner ， M L Yarmush ， et al . Liver-specific functional studies in a microfluidic array of primary mammalian hepatocytes [J]． Anal Chem ， 2006 ， 78 ( 13 )： 4291 - 4298 .

J DENG ， X L ZHANG ， Z Z CHEN ， et al . A cell lines derived microfluidic liver model for investigation of hepatotoxicity induced by drug-drug interaction [J]． Biomicrofluidics ， 2019 ， 13 ( 2 )： 024101 .

Y Y QU ， F AN ， Y LUO ， et al . A nephron model for study of drug-induced acute kidney injury and assessment of drug-induced nephrotoxicity [J]． Biomaterials ， 2018 ， 155 ： 41 - 53 .

K Jang ， A P Mehr ， G A Hamilton ， et al . Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment [J]． Integr Biol ， 2013 ， 5 ( 9 )： 1119 - 1129 .

E Weinberg ， M Kaazempur-Mofrad ， J Borenstein ． Concept and computational design for a bioartificial nephron-on-a-chip [J]． Int J Artif Organs ， 2008 ， 31 ( 6 )： 508 - 514 .

A Agarwal ， J A Goss ， A Cho ， et al . Microfluidic heart on a chip for higher throughput pharmacological studies [J]． Lab Chip ， 2013 ， 13 ( 18 )： 3599 - 3608 .

A Grosberg ， P W Alford ， M L McCain ， et al . Ensembles of engineered cardiac tissues for physiological and pharmacological study：heart on a chip [J]． Lab Chip ， 2011 ， 11 ( 24 )： 4165 - 4173 .

A Mathur ， P Loskill ， K Shao ， et al . Human iPSC-based cardiac microphysiological system for drug screening applications [J]． Sci Rep ， 2015 ， 5 ( 1 )： 1 - 7 .

D Huh ， Matthews ， D Benjamin ， et al . Reconstituting organ-level lung functions on a chip [J]． Science ， 2010 ， 328 ( 5986 )： 1662 - 1668 .

D Huh ， H Fujioka ， Y C Tung ， et al . Acoustically detectable cellular-level lung injury induced by fluid mechanical stresses in microfluidic airway systems [J]． Proc Natl Acad Sci USA ， 2007 ， 104 ( 48 )： 18886 - 18891 .

I Maschmeyer ， A K Lorenz ， K Schimek ， et al . A four-organ-chip for interconnected long-term co-culture of human intestine，liver，skin and kidney equivalents [J]． Lab Chip ， 2015 ， 15 ( 12 )： 2688 - 2699 .

F AN ， Y Y QU ， Y LUO ， et al . A laminated microfluidic device for comprehensive preclinical testing in the drug ADME process [J]． Sci Rep ， 2016 ， 6 ( 1 )： 1 - 8 .

陈江华，杨林，邓中平．山豆根中主要成分在Caco-2细胞模型上的转运特性 [J]．中国实验方剂学杂志， 2015 ， 21 ( 13 )： 5 - 8 .

Z LI ， Y GUO ， Y YU ， et al . Assessment of metabolism-dependent drug efficacy and toxicity on a multilayer organs-on-a-chip [J]． Integr Biol(Camb) ， 2016 ， 8 ( 10 )： 1022 - 1029 .

覃庆洪，黄敏，谭启杏，等．白藜芦醇苷对人类乳腺癌MCF-7细胞增殖的影响及其机制 [J]．中国实验方剂学杂志， 2018 ， 24 ( 4 )： 143 - 148 .

党珏，李燕，刘美辰，等．大黄有效成分与附子有效成分配伍在Caco-2细胞模型上的转运分析 [J]．中国实验方剂学杂志， 2018 ， 24 ( 7 )： 1 - 6 .

蔡润兰，王敏，齐云，等． Caco-2细胞模型验证指标的选择与评判 [J]．中国药学杂志， 2008 ， 43 ( 24 )： 1871 - 1875 .

余细勇，林曙光，杨敏，等．普萘洛尔及其代谢物4-羟普萘洛尔的药代动力学 [J]．中国临床药理学杂志， 1991 ， 7 ( 4 )： 233 - 240 .

王雪，修成奎，杨静，等．人参-三七-川芎提取物对高糖高脂诱导血管内皮细胞衰老的影响 [J]．中国实验方剂学杂志， 2019 ， 25 ( 1 )： 124 - 129 .

王庭槐．生理学 [M]．北京：高等教育出版社， 2004 ： 99 - 113 .

H Kimura ， T Ikeda ， H Nakayama ， et al . An on-chip small intestine-liver model for pharmacokinetic studies [J]． J Lab Autom ， 2015 ， 20 ( 3 )： 265 - 273 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Differences in Intestinal Absorption Characteristics of Nanophase in Single and Combined Decoctions of Ginseng Radix et Rhizoma and Zingiberis Rhizoma Recens Based on Everted Gut Sac Model

Investigation of Intestinal Absorption Characteristics of Multi-index Components of Danggui Buxuetang Based on Drug Absorption Simulating System

Effect of Berbamine Hydrochloride on Intestinal Absorption Characteristics of Berberine Hydrochloride by Rat Everted Intestinal Sac Model

Primary Culture Rat Vascular Adventitial Fibroblasts and Biological Behaviour Study

Related Author

GUO Xiaomeng

WANG Qi

LI Meijing

ZHANG Nan

GONG Muxin

Jia ZHANG

Yuan GAO

Xiangjie ZHOU

Related Institution

Beijing Key Laboratory of Traditional Chinese Medicine（TCM） Collateral Disease Theory Research，School of TCM，Capital Medical University

School of Pharmacy，Jiangsu Provincial Engineering Research Center of Traditional Chinese Medicine External Medication Development and Application，Jiangsu Provincial Engineering Research Center of Classical Formula，Nanjing University of Chinese Medicine

College of Pharmacy, School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine

Tibetan Medical College, Qinghai University

Key Laboratory of Modern Preparation of Traditional Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Construction of A Microfluidic Intestine-liver-breast Cancer Chip and Analysis of Its Application in PK-PD in Vitro of Drugs

DOI：10.13422/j.cnki.syfjx.20191749

摘要

Abstract

关键词

Keywords

references